FLGT Fulgent Genetics: שווי פעילות לרווח לפני ריבית, מסים ופחת

The EV/EBITDA valuation trend for Fulgent Genetics, Inc. (FLGT) reflects the dynamics of the company's partnerships with the public sector and clinics. Long-term contracts with medical networks support margin stability, although stricter FDA regulations and falling demand for COVID tests have reduced client inflow. The 0.00 mark indicates the business value relative to operating profit, helping to assess the asset's investment attractiveness.

Given the low cyclicality of genetic diagnostics at Fulgent Genetics, Inc. (FLGT), the EV/EBITDA multiple on the time chart demonstrates the resilience of the business value relative to its operating profit. This indicator aggregates market capitalization and net debt, dividing them by earnings before depreciation and amortization, which allows an investor to assess the actual payback period of the asset while accounting for the debt load.